Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients
Part of paid clinical trials in Manhattan Beach, California.
- Sponsor
- University of California, Los Angeles
- Study ID
- NCT07022574
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- IgA Nephropathy (IgAN)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Low inflammation diet intervention — BEHAVIORALAutoimmune Protocol Diet intervention
Study Details
This study at UCLA Center for Health Sciences is testing whether the Autoimmune Protocol (AIP) diet can lower protein levels in the urine of people with IgA Nephropathy (IgAN), a common kidney disease that can lead to kidney failure. The AIP diet avoids foods that may cause inflammation (like dairy, grains, and sugar) for 8 weeks, then gradually reintroduces them over 4 months. We're enrolling 30 adults aged 18-65 with IgAN and protein in their urine to try this diet for 6 months. Participants will track their urine protein daily at home, keep a food log, and have monthly lab checkups, with support from a diet expert. The main goal is to see if the diet reduces urine protein by 20% or more, which could slow disease progression and reduce the need for treatments like dialysis. This exploratory study aims to find out if diet changes can help manage IgAN.
Key Dates
- Start date
- Feb 1, 2026
- Status verified
- Jun 2025
- Primary completion
- Dec 1, 2027
- Completion
- Dec 1, 2027
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: AIP Intervention armAutoimmune Protocol Diet intervention
Primary Outcome Measure
Change from Baseline Urinary Protein to Creatine Ratio at 6months [ Time Frame: 6 months ]
Central Contacts
- Thuy T Tran, MD213-474-6452
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UCLA | Manhattan Beach | California | 90266 |
Find similar trials in Manhattan Beach, CA
Related Studies
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptPHASE2 · Enrolling By Invitation · Vera Therapeutics, Inc. · Brisbane, California
- Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)PHASE2 · Recruiting · Mayo Clinic · Jacksonville, Florida
- Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseasePHASE2 · Recruiting · ADARx Pharmaceuticals, Inc. · Doral, Florida